Intellia Therapeutics (NTLA) Shares Outstanding (Weighted Average) (2015 - 2026)
Intellia Therapeutics (NTLA) reported Shares Outstanding (Weighted Average) of $118.5 million for Q1 2026, up 14.48% year-over-year from $103.5 million in Q1 2025, and up 9.33% on a QoQ basis from $108.4 million in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of Shares Outstanding (Weighted Average) data on file, last reported at $118.5 million in Q1 2026.
- Quarterly Shares Outstanding (Weighted Average) rose 14.48% year-over-year to $118.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.5 million (up 14.48% YoY) and the FY2025 annual result came in at $108.4 million, up 9.64% from the prior year.
- Shares Outstanding (Weighted Average) rose to $118.5 million in Q1 2026 per NTLA's latest filing, from $108.4 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $118.5 million in Q1 2026 and bottomed at $74.8 million in Q1 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $95.5 million (2024), against an average of $93.2 million.
- The widest annual swing landed in 2023, when Shares Outstanding (Weighted Average) rose 17.42%; it then rose 6.85% in 2025.
- Tracing NTLA's Shares Outstanding (Weighted Average) over 5 years: stood at $77.0 million in 2022, then grew by 15.33% to $88.8 million in 2023, then advanced by 11.35% to $98.8 million in 2024, then increased by 9.64% to $108.4 million in 2025, then climbed by 9.33% to $118.5 million in 2026.
- Per Business Quant, the three latest NTLA Shares Outstanding (Weighted Average) figures stand at $118.5 million (Q1 2026), $108.4 million (Q4 2025), and $105.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | 118.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 118.49 Mn |
| Dec 31, 2025 | 108.38 Mn |
| Sep 30, 2025 | 105.84 Mn |
| Jun 30, 2025 | 103.62 Mn |
| Mar 31, 2025 | 103.50 Mn |
| Dec 31, 2024 | 98.85 Mn |
| Sep 30, 2024 | 97.84 Mn |
| Jun 30, 2024 | 96.98 Mn |
| Mar 31, 2024 | 95.50 Mn |
| Dec 31, 2023 | 88.77 Mn |
| Sep 30, 2023 | 88.20 Mn |
| Jun 30, 2023 | 88.19 Mn |
| Mar 31, 2023 | 87.77 Mn |
| Dec 31, 2022 | 76.97 Mn |
| Sep 30, 2022 | 76.05 Mn |
| Jun 30, 2022 | 75.28 Mn |
| Mar 31, 2022 | 74.75 Mn |
| Dec 31, 2021 | 70.89 Mn |
| Sep 30, 2021 | 69.72 Mn |
| Jun 30, 2021 | 67.68 Mn |
| Mar 31, 2021 | 67.18 Mn |
| Dec 31, 2020 | 55.99 Mn |
| Sep 30, 2020 | 54.22 Mn |
| Jun 30, 2020 | 51.94 Mn |
| Mar 31, 2020 | 50.49 Mn |
| Dec 31, 2019 | 47,247.00 |
| Sep 30, 2019 | 48.55 Mn |
| Jun 30, 2019 | 45.81 Mn |
| Mar 31, 2019 | 45.23 Mn |
| Dec 31, 2018 | 43.07 Mn |
| Sep 30, 2018 | 43.16 Mn |
| Jun 30, 2018 | 42.84 Mn |
| Mar 31, 2018 | 42.04 Mn |
| Dec 31, 2017 | 36.01 Mn |
| Sep 30, 2017 | 35.19 Mn |
| Jun 30, 2017 | 34.92 Mn |
| Mar 31, 2017 | 34.72 Mn |
| Dec 31, 2016 | 22.22 Mn |
| Sep 30, 2016 | 34.32 Mn |
| Jun 30, 2016 | 19.12 Mn |
| Mar 31, 2016 | 676,000.00 |
| Dec 31, 2015 | 243,000.00 |
| Sep 30, 2015 | 294,000.00 |
| Jun 30, 2015 | 1.28 Mn |
| Mar 31, 2015 | 1.28 Mn |